Abstract:Apoptosis as a novel target for cancer chemotherapy has generated an intense demand for new apoptosis-inducing agents. The newly revealed role of protein families involved in the apoptosis pathway, and resistance to cytotoxic therapies have opened new avenues for the development of novel anticancer strategies. We have established a novel strategy to rapidly obtain protein-targeted, instead of conventional DNA-targeted, apoptosis inducers as antitumor leads. First, a novel organic non-DNA intercalative compound S1 (8-oxo-3-thiomorpholin-4-yl-8H-acenaphto[1,2-b]pyrrole-9-carbonitrile, M-W = 331) was found with an IC50 of 10(-7)-10(-8) mu M against diverse cancer cell lines. Further biological evaluation demonstrated that it was an apoptosis-inducer both in vivo and in vitro. The treatment of hydroperitoneum hepatoma cells (H22 cell line) with S1 at various concentrations (from 0.01 to 10 mu M) for 24 h triggered these cells to enter the apoptosis process. The antitumor efficiency was also tested in the H22 xenotransplant models in mice. At a dosage of 0.3 mg kg(-1), S1 exhibited significant antitumor activity with a much longer survival time, a decrease in tumor size, and increased apoptosis cells in tumor tissue. More importantly, studies of the molecular mechanism of apoptosis induction by S1 revealed that S1 inactivated the Bcl-2 protein by binding to it, depolarizing the mitochondrial membrane, and then activating caspase 9, followed by caspase 3. Finally, structure-based virtual modification was performed by computer modeling. As a result, a derivative, S2 (8-oxo-3-[(thienylmethyl)amino]-8H-acenaphtho[1,2-b]pyrrole-9-carbonitrile, M-W = 341) was identified that possessed a lower binding energy to Bcl-2, and demonstrated better antitumor potency, even on the Bcl-2-overexpressing human acute myeloid leukemia (HL-60) cells (IC50 = 1.3 mu M) in vitro. S1 and S2 are the well-defined Bcl-2 inhibitors that give us a promising platform for the development of new therapeutic agents.

Development of XIAP Antagonists Based on De Novo 8,5-Fused Bicyclic Lactams.

Design, Synthesis, And Interaction Study Of Quinazoline-2(1h)-Thione Derivatives As Novel Potential Bcl-X(L) Inhibitors

Novel X-linked Inhibitor of Apoptosis Protein Inhibitors As Probes of Apoptosis in Biology and Medicine

Structure based pharmacophore modeling, virtual screening, molecular docking and ADMET approaches for identification of natural anti-cancer agents targeting XIAP protein

Design, synthesis, and biological activities of novel hexahydropyrazino[1,2-a]indole derivatives as potent inhibitors of apoptosis (IAP) proteins antagonists with improved membrane permeability across MDR1 expressing cells

Design and synthesis of a simplified inhibitor for XIAP-BIR3 domain

Design, Synthesis and Pharmacological Evaluation of New Acyl Sulfonamides As Potent and Selective Bcl-2 Inhibitors.

Design, Synthesis, and Structure-Activity-relationship of a Novel Series of CXCR4 Antagonists.

Discovery of Embelin As a Cell-Permeable, Small-Molecular Weight Inhibitor of XIAP Through Structure-Based Computational Screening of a Traditional Herbal Medicine Three-Dimensional Structure Database

XIAP as a Target of New Small Organic Natural Molecules Inducing Human Cancer Cell Death

Design, Synthesis, Biological Evaluation and Molecular Docking Study on Peptidomimetic Analogues of XK469

Theoretical Studies on the Interactions of XIAP-BIR3 Domain with Bicyclic and Tricyclic Core Monovalent Smac Mimetics

Towards New Anti‐inflammatory Agents: Design, Synthesis and Evaluation of Molecules Targeting XIAP‐BIR2

Design and application of a rigid quinazolone scaffold based on two-face Bim α-helix mimicking.

Structure–activity Based Study of the Smac-binding Pocket Within the BIR3 Domain of XIAP

Discovery, Design and Synthesis of 6H-Anthra[1,9-cd]isoxazol-6-one Scaffold As G9a Inhibitor Through a Combination of Shape-Based Virtual Screening and Structure-Based Molecular Modification

Development of 3‐phenyl‐n‐(2‐(3‐phenylureido)ethyl)‐thiophene‐2‐sulfonamide Compounds As Inhibitors of Antiapoptotic Bcl‐2 Family Proteins

Novel Bcl‐2 Inhibitors: Discovery and Mechanism Study of Small Organic Apoptosis‐Inducing Agents

Design, synthesis, and evaluation of tricyclic, conformationally constrained small-molecule mimetics of second mitochondria-derived activator of caspases.

Novel Spiropyrazolone Antitumor Scaffold with Potent Activity: Design, Synthesis and Structure–activity Relationship

Design, in silico evaluation, and in vitro verification of new bivalent Smac mimetics with pro-apoptotic activity